LAS VEGAS, NEVADA, November 20,
2024 -- InvestorsHub NewsWire -- Avant Technologies Inc.
(OTCQB:
AVAI) (“Avant” or the “Company”), and its partner Ainnova Tech,
Inc., (Ainnova) a leading healthcare technology company focused on
revolutionizing early disease detection using artificial
intelligence (AI), today announced the companies will advance
Ainnova’s proprietary low-cost retinal camera, which will be used
for fundus photography, and seamlessly packaged together with
Ainnova’s Vision AI software platform for commercialization. By
combining the two technologies, Ainnova’s versatile camera will
provide precise retinal scans to its AI software leading to even
more accurate data.
Vision AI is a powerful
cutting-edge, AI-driven platform that can quickly and accurately
detect the early markers of a host of diseases by applying AI
models to examine imaging data from the eye to expedite earlier
detection and allow patients to better manage their disease. The
diseases that Vision AI can detect, include diabetic retinopathy,
other retinopathies, such as glaucoma, macular edema, age-related
macular degeneration and other anomalies, as well as other diseases
that do not require retinal images, and instead, use other
datapoints that Ainnova will integrate into the software like the
detection of kidney disease, liver fat, cardiovascular risk, and
pre-diabetes.
Currently, Ainnova’s Vision AI
software works well with any fundus camera on the market; however,
Ainnova and Avant are aiming for exclusivity by developing a
lower-cost, easier to use camera that captures retinal images
automatically and then uploads those images to the Vision AI
software platform, which then produces a “risk report” in mere
seconds. Ai-nova Acquisition Corp. (AAC), the company formed by the
partnership between Avant and Ainnova, will develop the retinal
cameras as part of the joint venture and licensing deal to
facilitate the development of Ainnova’s technology portfolio. AAC
owns the licensing rights to develop, maintain, and market
Ainnova’s technology portfolio in both North America (United States
and Canada) and throughout Europe.
Vinicio Vargas, Chief Executive
Officer of Ainnova and member of AAC’s Board of Directors, said,
"The cost of a fundus camera has always been a barrier to entry
into in this market, so our low-cost camera should allow us to not
only enter the market, but to capture a large share of the market.
To that end, I will be meeting with a leading U.S. provider of
digital healthcare solutions to discuss a potential distribution
agreement, investment, and regulatory support."
AAC will market the two
technologies as a Software as a Service (SaaS) + retinal camera
package with the hope of making retinal scans a part of routine
healthcare. The business model is a pay-per-use platform, per
patient, monthly, aimed at primary care clinics, insurance
companies, opticians, pharmacies, occupational health companies
that provide the service to employees of many companies, and
pharmaceutical companies that sell the treatments or therapies.
Vinicio Vargas added, "Our vision
is that the retina will be a new standard in primary care, as basic
as taking a patient’s blood pressure, and together with other
datapoints, such as demographic data or laboratory results, to
generate a complete report of preventive medicine.
"The goal is to provide patients
with a risk screening so that they can be referred to the
appropriate specialist. Our proprietary retinal camera, combined
with our VisionAI software technology will offer a real accessible
opportunity for early detection - and this is how we are going to
impact the world."
Ainnova currently has commercial
agreements with pharmaceutical companies, clinics, insurance
companies, and medical service providers, and these relationships
should offer AAC guidance into marketing the SaaS + retinal camera
package in the North American and European markets.
About Ainnova Tech,
Inc.
Ainnova is a Nevada-based
healthtech startup with headquarters in San Jose, Costa Rica, and
Houston, Texas. Founded by an experienced and innovative team that
is dedicated to leveraging artificial intelligence for early
disease detection. Recognized with multiple global awards and
renowned partnerships with hospitals and medical device companies,
we proudly introduce VisionAI - our cutting-edge platform designed
to prevent blindness and detect the early onset of diabetes.
Explore how Ainnova is revolutionizing healthcare through advanced
technology and proactive solutions.
About Avant Technologies,
Inc.
Avant Technologies, Inc. is an
emerging technology company developing solutions in artificial
intelligence in healthcare. With a focus on pushing the boundaries
of what is possible in AI and machine learning, Avant serves a
diverse range of industries, driving progress and efficiency
through state-of-the-art technology.
More information about Avant can be
found at https://avanttechnologies.com
You can also follow us on social
media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking
Statements
Certain statements contained in
this press release may constitute “forward-looking statements.”
Forward-looking statements provide current expectations of future
events based on certain assumptions and include any statement that
does not directly relate to any historical or current
fact. Actual results may differ materially from those
indicated by such forward-looking statements because of various
important factors as disclosed in our filings with the Securities
and Exchange Commission located at their website (http://www.sec.gov). In addition to these
factors, actual future performance, outcomes, and results may
differ materially because of more general factors including
(without limitation) general industry and market conditions and
growth rates, economic conditions, governmental and public policy
changes, the Company’s ability to raise capital on acceptable
terms, if at all, the Company’s successful development of its
products and the integration into its existing products and the
commercial acceptance of the Company’s products. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect
to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing the Company's views as of any date after the date of
the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
Avant Technologies (QB) (USOTC:AVAI)
過去 株価チャート
から 10 2024 まで 11 2024
Avant Technologies (QB) (USOTC:AVAI)
過去 株価チャート
から 11 2023 まで 11 2024
